While doxorubicin-based polychemotherapy has been the standard treatment for ALK + ALCL [21], crizotinib, the first FDA-approved ALK tyrosine kinase inhibitor, has been used clinically [22,23]. Here, ALK is linked to anaplastic large cell lymphoma.